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Abstract: The future hope of generated induced pluripotent stem cells (iPS cells) from 
Alzheimer’s disease patients is multifold. Firstly, they may help to uncover novel 
mechanisms of the disease, which could lead to the development of new and 
unprecedented drugs for patients and secondly, they could also be directly used for 
screening and testing of potential new compounds for drug discovery. In addition, in the 
case of familial known mutations, these cells could be targeted by use of advanced  
gene-editing techniques to correct the mutation and be used for future cell transplantation 
therapies. This review summarizes the work so far in regards to production and 
characterization of iPS cell lines from both sporadic and familial Alzheimer’s patients and 
from other iPS cell lines that may help to model the disease. It provides a detailed 
comparison between published reports and states the present hurdles we face with this new 
technology. The promise of new gene-editing techniques and accelerated aging models 
also aim to move this field further by providing better control cell lines for comparisons 
and potentially better phenotypes, respectively. 
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1. Introduction 
Alzheimer’s disease (AD) is an incurable age-associated disorder characterized by progressive 
neurodegeneration and is the most common type of dementia, currently affecting 35.6 million people 
worldwide, which is a figure that is expected to triple by 2050 [1]. The majority of cases have  
a development of late-onset symptoms (after the age of ~65), which include personality/behaviour 
changes and memory deficits, hindering general, everyday activities [2]. This late-onset form is most 
often the sporadic form of AD (SAD), whereby increasing age is the greatest risk factor, but may also 
be associated with unknown environmental exposures, or a family history of AD. Mutations in the 
polymorphic apolipoprotein E (APOE) gene are known to increase the risk in developing late-onset 
AD and it is further believed that this complex disease involves other susceptibility genes and/or 
spontaneous mutations in unknown genes [3–5]. Genetic factors account for approximately 80% of the 
risk for AD, and genome-wide association studies (GWAS) have identified several candidate genes 
besides APOE that may be associated with late-onset disease, including ABCA7, BIN1, CD33, CLU, 
CR1, CD2AP, EPHA1, MS4A6A-MS4A4E, PICALM, HLA-DRB5-DRB1, SORL1, FERMT2, CASS4, 
PTK2B, amongst others [6–10]. However, these susceptibility loci explain only around half of the total 
genetic variance and extensive further analyses are still necessary to characterize these candidate genes 
and elucidate their association with AD risk. Less than 5% of AD patients manifest symptoms at an 
earlier stage (before the age of 65), i.e., familial AD (FAD), which is linked to genetic mutations in 
one of three genes, including, amyloid precursor protein (APP), presenilin1 (PSEN1) and presenilin 2 
(PSEN2) [11]. PSEN1 accounts for the majority of FAD cases, whereas, PSEN2 and APP mutations 
are rarer and some FAD cases are not caused by mutations on any of these genes [12]. In this review, 
we provide an overview of the current status in the development of patient-specific induced pluripotent 
stem (iPS) cells derived from AD patients and how these cells may help sufferers of the disease, with 
respect to basic research findings, drug discovery and other treatments that may prospectively benefit 
the patients. 
2. AD Pathology and Progression 
The pathophysiology of the disease is not well understood and considering the prevalence and poor 
prognosis of AD, there has been a research priority in developing disease models for studying 
pathogenicity and to aid in development of therapeutic approaches. The difficulty in accessing brain 
samples from patients, along with the fact that only post-mortem brain analysis allows a definite AD 
diagnosis, makes iPS cells technology highly relevant in this context. That is, these cells, which are 
produced from directly reprogrammed AD patient somatic cells (e.g., dermal fibroblasts) into neuronal 
cells [13], will help us gain access to the disease in a dish, which would be much easier to study. 
Two pathological hallmarks are known to occur in the patient’s brain, however, it remains unclear 
which of these appear first and/or is mainly responsible for the disease’s progress [11,14]. One 
hallmark is the development of senile neuritic plaques, composed of extracellular accumulation of 
Amyloid-β (Aβ). These are formed from the extracellular deposition of Aβ monomers, which 
aggregate as amyloid fibrils outside of the neurons. There is much evidence to support the Amyloid 
hypothesis, which suggests these plaques are largely responsible for extensive synaptic loss and 
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neuronal death in the disease [15,16]. Tauopathy, the second hallmark, refers to intracellular 
neurofibrillary tangles (NFTs) of hyperphosphorylated cytoskeletal protein tau, which are known to 
destabilize axonal microtubules and lead to cell loss [17]. These tangles are also considered by many to 
be the leading cause of the disease and which is described as the tau hypothesis. Both the Amyloid 
hypothesis and the tau hypothesis remain leading contenders for the underlying cause of the disease. 
Staging of AD progression based on cortical neurofibrillary changes and increased expression  
of abnormal tau on postmortem brains reveal that Stage I (asymptomatic) initiates first in the 
periallococortical transentorhinal region of the temporal mesocortex located on the medial surface of  
the rhinal or collateral sulcus [18]. Stage II (asymptomatic) is evident to have spread to the layer pre-α 
or layer II of the entorhinal region and even deeper into the transentorhinal region. In stage III, lesions 
have progressed into the hippocampus, the layers pre-α and pri-α of the deep entorhinal layers, the 
temporal mesocortex and the high order sensory association areas of the temporal neocortex. In stage 
IV, the Ammon’s horn, the insular cortex and the medial temporal gyrus become affected [18]. Stage 
V is characterized by progression of lesions into the superior temporal gyrus and slightly affecting the 
premotor and first order sensory association areas of the neocortex [18]. The peristriatic region and 
parastriate area of the occipital lobe are also affected. The final stage VI ultimately resulting in death, 
is characterized by progression to the parastriate area and Brodman area of the first order sensory 
association areas and primary areas of the neocortex [18]. 
As a consequence, varying neural cells are affected, including, glia and neurons, such as  
pyramidal neurons, interneurons and specific neurons such as basal forebrain cholinergic neurons 
(BFCNs) [18–24]. In addition, extensive inflammation, glycation defects, deficiencies in the cell cycle 
in primary neurons, oxidative stress and endoplasmic reticulum stress-induced apoptosis have also 
been implicated in the disease [25–33]. 
3. Requirement for Further Basic Research into the Disease 
With the difficulties in obtaining patient brain samples and a lack of adequate animal models of  
the disease, AD research is considerably hampered. Since discovering genetic mutations within FAD, 
several transgenic animal models (mostly rodent) containing single mutations (in PSEN, APP and tau) 
have been made [34–37]. These models have explained, to some extent, the pathogenicity of soluble  
Aβ oligomers and the connection between amyloidopathy and tauopathy, but failed to recapitulate the 
complete pathology observed in humans. For example, the transgenic AD mouse model (the PDAPP 
mouse), which overexpresses human APP containing the Indiana mutation (V717F) [34], has senile 
plaques, age-related Aβ accumulation and synaptic loss, however fails to show the presence of NFTs. 
Hsiao and colleagues developed the most studied AD transgenic model (Tg2576 mice), which 
overexpresses the human APP transgene containing the Swedish mutation (K670N/M671L) [35]. 
These mice also show age-related Aβ deposition, an increased Aβ1-42/Aβ1-40 soluble ratio, plus 
senile plaques, however, fail to show any neuronal loss [38]. Several other transgenic models have 
since been generated [39–42] and Aβ deposits and cognitive decline were widely reported in these 
models, but not NFTs or neuronal loss. The crossing of lines or production of double, triple or multiple 
mutations appear to mimic AD pathology even better, including in some cases, NFT-like lesions and 
neuronal death [43–47]. Unfortunately, the use of this multiple gene-strategy to induce widespread 
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pathological features in the rodent differs considerably to familial human AD patients, which carry 
only single mutations. Furthermore, the use of these rodent models for pharmacological testing and 
evaluation of candidate drug targets has not led to the development of many successful drugs to  
date [48,49]. Staggeringly, it has been reported that hundreds of candidate drugs have failed during 
drug development [50] and it may simply be that our animal models are currently not optimal for either 
drug discovery or drug testing [49]. Emerging research indicates that in vitro human cell models of the 
disease may serve as more suitable models for recapitulating both the amyloid and tau hallmarks of the 
disease. One recent paper has reported that human neural progenitors cultured in vitro in 3D 
overexpressing either or both human APP and PSEN1 genes containing FAD mutations could display 
both increased Aβ40 and Aβ42 expression, increased extracellular Aβ deposits, increased insoluble Aβ 
and increased phosphorylated tau (p-tau) in a proportion of differentiated neurons. Such evidence 
definitely helps to pave the way for future research into disease modeling using human-based cell 
culture systems. 
Currently, there is no cure for AD or available drugs for the disease that can prevent progression  
long-term. Healthcare systems are over-loaded with dementia patients, which costs the society 
globally, around $604 billion (US dollars, 2010), making the disease a heavy economic burden on 
society [1]. With the ever-increasing age of the population and lack of highly successful clinical trials, 
it has become an urgent necessity to find enhanced treatments for AD. The prospect of even a slight 
improvement and delay in clinical onset of the disease within patients would have a great economic 
and social impact [51]. Reliable biomarkers are also very much needed since they allow for the in vivo 
detection of AD pathology in “normal” asymptomatic individuals [51]. Imaging technologies (i.e., 
PET scans) and cerebrospinal fluid biomarkers have been developed and can detect certain indications 
of AD pathology in humans, but their predictive capacity at an individual level is still not reliable [11]. 
Moreover, these tests have been mainly used in a research environment and the question of whether 
they should be applied widely in clinics is still debatable, due to the lack of adequate testing in 
preclinical and clinical trials [11]. 
4. Hope in Modeling Alzheimer’s Disease Using Patient-Specific Induced Pluripotent Stem Cells 
The development of iPS cells emerged in 2006, when mouse fibroblasts were successfully 
reprogrammed into pluripotent stem cells by retroviral-delivery of four transcription factors (Oct3/4, 
Sox2, c-Myc and Klf4), which activated an endogenous pluripotent state in somatic cells [52]. These 
iPS cells resembled embryonic stem cells (ESCs) [53], both in their expression profile, their ability to 
grow indefinitely and their ability to differentiate into all cell lineages of the body, including ectoderm, 
mesoderm and endoderm [52]. These cells have the potential to contribute to chimeras and to be 
transmitted through these chimeras into the germline, further proving their pluripotency [54]. The same 
and similar sets of factors were then applied to adult human fibroblasts [55–57]. It is reported these 
cells truthfully mimic human ESCs, however the reprogramming process is thought to induce some 
disparity at both the genetic and epigenetic levels [58–61]. Viral-delivery methods have shown good 
efficiency but also result in random integration of the transgenes into the genome, potentially leading 
to insertional mutagenesis and tumorigenicity, therefore restricting its use for future potential clinical 
trials [62]. More recently, integration-free reprogramming systems, including episomal plasmids 
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containing the reprogramming factors, Sendai virus, direct mRNA, protein and small molecules, have 
all been successfully used for generation of potentially transgene-free human iPS cells [56,63–65]. 
Moreover, xeno- and feeder-free culture methods have also helped to decrease variability between 
lines generated [66,67]. In addition, other cell types from patients have been successfully and safely 
used for reprogramming. As an alternate to dermal skin fibroblasts (acquired from surgical skin 
biopsies), peripheral blood mononuclear cells (PBMCs) (which are easy to harvest from routine 
peripheral blood samples) have been used to isolate T cells and generate human iPS cells [68,69]. One 
advantage is that the reprogramming of these cells can also be done quickly, with no need for prior 
expansion. These protocols therefore facilitate the production of human iPS cells from human somatic 
cells with minimal invasiveness. Together, these mentioned advances in production of human iPS cells 
might allow research to fulfill the restricted guidelines of Good Manufacturing Practices (GMPs) for 
the development of clinically-approved iPS cells required in the regenerative medicine field [70]. 
5. Therapeutic Benefits 
The discovery of iPS cells is groundbreaking, as it means that patient-specific cell lines can be 
established easily. Contrary to human iPS cells, human ESCs have been surrounded by ethical 
controversy due to the use of human embryos, which is a serious problem in terms of sample 
availability and public acceptance [71]. Human iPS cells are also clinically advantageous since the use 
of autologous tissue ideally surpasses the patient’s immune rejection, contrary to the allogeneic 
barriers of human ESCs [72]. Therapeutic cloning also allows the generation of pluripotent stem cells 
that are genetically similar to patients, however this requires the destruction of donor eggs or embryos 
and still has several technical issues [73,74]. Moreover, considering the unavailability of in vitro 
human disease models, human iPS cells could help to provide large numbers of patient-specific 
neuronal cells for research and clinical objectives. Pairing of both human iPS cell technology and 
advances in genome-editing technologies may also provide more robust findings since isogenic cell 
lines could lead to the replacement of age- and sex-matched controls [75–78]. Experimentally, this 
would allow for more phenotypic findings attributed to the genetic difference causing the disease, 
which would not be influenced by individual epigenetic differences [79]. Moreover, disease and 
population heterogeneity can also be diminished due to singular-patient origin of human iPS cells. 
Regenerative medicine, including testing of transplantation of cells into live tissues and organs is 
ongoing for AD models of rodents, such as neural progenitor cells (NPCs) [80–86] and mesenchymal 
stem cells [87–89], but remains restricted in relation to transplantation of ESC or iPS-derived neural 
cells [80,90]. Some research, however, does suggest that implanted cells do not survive and that the 
beneficial effect may likely come from their secretion of BDNF (brain-derived neurotrophic factor) 
and GDNF (glial cell-derived neurotrophic factor) [82]. Due to improved immunocompatibility in the 
use of autologous iPS cells, there is considerable hope that differentiated progeny of patient-specific 
iPS cells may be favorable for transplantation. 
In addition, human iPS cells are already being used for drug development and screening in various 
diseases [91] to identify new and superior targets relevant for production of new drugs. In the future,  
it may even be possible to provide patient-customized cell screens from the iPS-derived cells to screen 
a panel of drugs in order to identify the most beneficial treatment plan for each individual patient [92]. 
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This could have significant impact in treating this disease where patient variability is wide in response 
to certain drugs [93]. The development of patient-specific iPS cells may also help researchers to 
identify new mechanisms/biomarkers which may help lead to earlier diagnoses of the disease [94] as it 
is possible to culture early neurons or NPCs which may have underlying deficits related to the disease. 
It is also believed that earlier intervention is a key factor for a successful therapeutic strategy and an 
earlier diagnosis would be of extreme benefit to patients, as the initial stages of the disease could be 
treated whilst the patients are still early symptomatic [51]. It is crucial for clinical trials to target these 
early symptomatic patients, therefore facilitating therapeutic procedures to succeed in delaying, 
stopping or even preventing the cognitive decline [51]. We summarize the implications patient-specific 
iPS cells have on basic research as well as therapeutic benefits for AD in Figure 1. 
Figure 1. Schematic illustration of the use of induced pluripotent stem (iPS) cells in 
relation to Alzheimer’s disease (AD). (A) iPS cells are derived from a skin biopsy from an 
AD patient and differentiated into neural progenitor cells and neurons; (B) In familial 
cases, the disease-causing mutation can be corrected by gene-editing of the iPS cells, and 
neural progenitor cells and neurons can be used for research and drug screening; (C) The 
patients can in the long run benefit from these activities by cell therapy, better diagnostic 
procedures, customized treatments and novel medical approaches. 
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6. Induced Pluripotent Stem Cells and Neural Cell Derivatives Have Been Produced from 
Several AD Patients 
The discovery of iPS cells paved the way to model diseases by using patient-specific cells which 
can then be differentiated into disease relevant cell types. However, despite this breakthrough, there 
have been surprisingly only a handful of studies published on Alzheimer’s disease [95–102,103]. 
Induced pluripotent stem cells have now been derived from both familial and sporadic patients and 
these iPS cells have been differentiated into varying neurons and glia, which have been studied in 
respect to specific AD pathology. Here, we summarize the types of cells analyzed and the extent of 
their characterization (Table 1). The genetic backgrounds of patients that have been used to date,  
include, duplication or mutations of APP, mutations of PSEN1 and PSEN2, in the case of familial  
AD [96–99,101,102] and mutations in APOE3/E4 resulting in both early sporadic and late sporadic 
forms of the disease [95]. It should be stated that in the case of one study [98], the APP (E693∆) 
mutation background (which is responsible for Alzheimer-type dementia [104]) showed no evident tau 
pathology and lack of fibrilization of Aβ peptides. Therefore not all hallmark pathologies would be 
anticipated in the iPSC-derived neurons. We also include a study where a Down-syndrome iPS cell 
line was used to model features of AD [100], since it could clearly model varying pathological features 
of the disease. 
In each article, different types of neural cells have been analyzed, which have been derived using 
various differentiation protocols (see overview of protocols in Table 2). Cortical neurons have been 
studied by both Shi and colleagues and Kondo and colleagues [98,100]. Forebrain neurons have been 
studied by Muratore and colleagues [103]. Astrocytes (GFAP+) have also been studied by Kondo and 
colleagues [98] and basal forebrain cholinergic neurons (BFCNs) have been studied by Duan and 
colleagues [95]. GABAergic neurons have been studied by Koch and colleagues [97], whereas, more 
less-defined neurons (βIIITubulin+/MAP2+) have been studied by Israel and colleagues, Yagi and 
colleagues, Liu and colleagues and Sproul and colleagues [96,99,101,102]. Whilst some protocols  
used FACS to sort and purify the neural cell populations (e.g., sorting of CD24+CD184−CD44−  
neurons [96,101] and Lhx8+/Gbx1+ neurons [95]), it is without doubt that all the final cell populations 
analyzed had some degree of cell heterogeneity, as often observed by the percentages of positive cells 
stated. Three particular articles performed extensive characterization of the types of neurons generated. 
In the case of the generation of BFCNs, immunocytochemistry confirmed their mature features, since a 
large proportion expressed ChAT and VaChT, and all were found to be HB9 negative (a selective 
marker of motor neurons in the vertebrates) (Table 2). 
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Table 1. Phenotypes of neural cells analyzed from differentiated patient-specific induced pluripotent stem cells for studying Alzheimer’s disease. 
Mutation Cell Type Analyzed Analyses Performed Phenotype Reference 
Familial  
PSEN1 (A246E) 
2 clones Neurons  
(βIIITubulin+ 
MAP2+) 
Extracellular Aβ  
Tau accumulation (HT7 
antibody)  
Tangle formation  
Treatment with γ-secretase 
inhibitor and modulator of  
γ-secretase-mediated  
APP cleavage 
Increased Aβ42:Aβ40  
No Tau accumulation  
No tangle formation  
Decreased Aβ40+Aβ42 with γ-secretase inhibitor and modulator of  
APP cleavage 
[99] 
Familial  
PSEN2 (N141I) 
2 clones 
Familial  
APP dup’n  
APPDp1  
3 clones 
Neurons  
(βIII-Tubulin+ 
MAP2+)  
>90% 
Genome-wide mRNA seq.  
Extracellular Aβ  
p-tau (Thr231)  
GSK-3β activity  
Treatment with γ-secretase and 
β-secretase inhibitors  
Endosome markers  
Synaptic markers 
Increased Aβ40, Increased p-tau (Thr231), Increased aGSK-3β  
γ-/β-secretase inhibitors reduced Aβ40  
[96] 
Familial  
APP dup’n  
APPDp2  
3 clones 
Increased Aβ40  
Increased p-tau (Thr231), Increased aGSK-3β  
γ-/β-secretase inhibitors reduced Aβ40  
β-secretase inhibitor reduced aGSK-3β+p-tau 
had large/very large Rab5 + early endosomes  
No change in synapsin I + puncta on dendrites 
Sporadic  
sAD1  
3 clones 
No change in Aβ40, No increase of p-tau (Thr231), No increase aGSK-3β 
γ-/β-secretase inhibitors reduced Ab40 
Sporadic  
sAD2  
3 clones 
No change in Aβ40  
Increased p-tau (Thr231) and aGSK-3β  
γ-/β-secretase inhibitors reduced Aβ40  
β-secretase inhibitor reduced aGSK-3β+p-tau  
had large/very large Rab5 + early endosomes 
No change in synapsin I + puncta on dendrites 
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Table 1. Cont. 
Mutation Cell Type Analyzed Analyses Performed Phenotype Reference 
Familial  
PSEN1 (D385N)
It-NES progenitor cells (NESTIN+SOX2+)
Expression APP+  
γ-secretase components  
Extracellular Aβ  
Aβ length  
qPCR 
Dominant-negative effect on S3 cleavage of Notch 
in progenitors, decreased HES5 
[97] 
Neurons  
(βIII-Tubulin+MAP2ab+ 
GABA+) + <10% Astrocyte (GFAP+) 
Increased full-length APP  
Decreased Aβ40 
Familial  
PSEN1 (L166P) 
It-NES cells (NESTIN+SOX2+) 
Dominant-negative effect on S3 cleavage of Notch 
in progenitors, decreased HES5 
Neurons (βIII-Tubulin+MAP2ab+ 
GABA+) <10% Astrocyte (GFAP+) 
Decreased Aβ40 
Trisomy 21  
DS1-iPS4 
Cortical neurons;  
Early born,  
(TBR1+ 
βIII-Tubulin+ 
/CTIP2+ 
βIII-Tubulin+) 30%  
Late born,  
(BM2+ 
βIII-Tubulin+/SATB2+ 
βIII-Tubulin+) 20%–25%  
Functional synapses 
Glutamatergic (PSD95+) 
Extracellular Aβ  
Aggregation of Aβ  
Treatment with  
γ-secretase inhibitor  
p-tau expression  
Cell death 
Increased Aβ40 
Increased Aβ42 (>70 days cultures)  
Increased Aβ42:Aβ40  
Intracellular and extracellular Aβ42 aggregates  
Decreased Aβ40+Aβ42 with γ-secretase inhibitor  
p-tau localized in cell bodies and dendrites  
Increased secretion of total tau and p-tau  
Increased cell death (2 fold) 
[100] 
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Table 1. Cont. 
Mutation Cell Type Analyzed Analyses Performed Phenotype Reference 
Familial  
APP(E693) 3 clones
Cortical neurons 
(SATB2+TBR1+) 
Extracellular Aβ  
Intracellular Aβ  
Aβ Oligomers  
Gene expression 
profiling  
ROS expression  
Aβ Oligomers  
ROS expression 
Decreased Aβ40 and Aβ42  
Elevated Aβ oligomers in neural cells  
Elevated levels of oxidative stress-related genes  
Elevated ROS 
[98] 
Astrocytes 
Elevated Aβ oligomers  
Elevated ROS 
Familial  
APP(V717L) 2 clones
Cortical neurons 
(SATB2+TBR1+) 
Increased Aβ42, increased Aβ42:Aβ40  
Elevated levels of oxidative stress-related genes 
Sporadic AD3E211  
1 clone 
Cortical neurons 
(SATB2+TBR1+) 
No change in Aβ40 or Aβ42  
Elevated levels of oxidative stress-related genes 
Sporadic AD8K213  
1 clone 
Cortical neurons 
(SATB2+TBR1+) 
No change in Aβ40 or Aβ42  
Elevated Aβ oligomers in neural cells  
Elevated levels of oxidative stress-related genes and ROS 
Astrocytes Elevated Aβ oligomers, Elevated ROS 
Sporadic  
Early ApoE3/E4  
AG04402 (2 clones) 
Basal forebrain cholinergic 
neurons 
(MAP2+ChAT+ 
VaChT+P75R+NKX2.1+HB9−) 
Expressed tetrodotoxin-sensitive 
voltage-activated currents and 
voltage-gated calcium channels 
Extracellular Aβ  
Treatment with  
γ-secretase inhibitors  
Treatment with 
ionomycin + glutamate 
Fura-2 calcium imaging
Elevated Aβ42, Increased Aβ40 with γ-secretase inhibitor  
Increased susceptibility to glutamate-induced excitotoxic death 
Increased calcium transient 
[95] 
Sporadic  
Early, APOE3/E4  
AG11414 
Elevated Aβ42  
Increased Aβ40 with γ-secretase inhibitor  
Susceptibility to cell death following calcium influx 
Sporadic Late 
APOE3/E4 AG05810 
No elevated Aβ42  
Increased susceptibility to glutamate-induced excitotoxic death 
Increased calcium transient 
Familial  
AG07872 
Elevated Aβ42  
Reduced Ab40 with γ-secretase inhibitor 
Familial  
PSEN1 (A246E)  
AG066848 
No elevated Aβ42  
Reduced Aβ40 with γ-secretase inhibitor 
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Table 1. Cont. 
Mutation Cell Type Analyzed Analyses Performed Phenotype Reference 
Familial  
APP (V717I)  
(fAD1)  
(2 clones) 
Forebrain neurons  
(MAP2+Tau+ 
βIII-Tubulin+Cux1+ 
TBR1+PSD95+ 
VGLUT1+) 
Extracellular Aβ  
APP cleavage product 
expression  
Treatment with γ-secretase 
inhibitor  
Expression of tau  
Treatment with Aβ antibodies 
APP holoprotein 1.4× increased  
Increased Aβ42:Aβ40  
Increased Aβ42  
Increased Aβ38  
Decreased APPsα:APPsβ (Increased APPsβ)  
γ-secretase inhibitor blocked APPsβ cleavage  
Increased total tau  
Increased p-tau (Ser262) d100  
Aβ antibodies blocked increased total tau (early 
differentiated neurons only) 
[103] 
(fAD2) asymptomatic 
(2 clones) 
Familial  
PSEN1  
(A246E)  
(2 patients) 
Neurons  
(βIII-Tubulin+MAP2+) 
Extracellular Aβ  
Treatment with γ-secretase 
inhibitors 
Increased Aβ42:Aβ40  
Increased Aβ42  
γ-secretase inhibitor lowered total Aβ, Aβ40, 
Aβ42, Aβ38 
[101] 
PSEN1  
(H163R)  
asymptomatic 
Increased Aβ42:Aβ40  
Increased Aβ42  
-secretase inhibitor lowered Aβ42 
PSEN1  
(M146L) 
Increased Aβ42:Aβ40  
Increased Aβ42  
γ-secretase inhibitor lowered Aβ42 
Familial; PSEN1  
(A246E)  
(2 clones)  
7671C/7768C 
D14 immature neurons (79% 
NESTIN+ small pop’n TUJ1+)
Extracellular Aβ  
Total Aβ 
Increased Aβ42:Aβ40  
Increased NLRP2, ASB9, NDP 
[102] 
Neurons 
Electrical signaling properties 
Increased Aβ42:Aβ40 
PSEN1  
(M146L)  
(2 clones)  
8446B/8446D 
D14 immature neurons (79% 
NESTIN+ small pop’n TUJ1+)
Increased Aβ42:Aβ40  
Increased NLRP2, ASB9, NDP 
Neurons  
Electrical signaling properties 
Increased Aβ42:Aβ40 
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Table 2. Reprogramming and differentiation strategies for induction of induced pluripotent stem cells and their neural progeny. 
Reprogramming Strategy Differentiation Protocol Cell Type Formed Reference 
Retrovirus  
OCT4, SOX2, KLF4, LIN28, 
NANOG  
Human dermal fibroblasts 
EB induction w/o bFGF 8 days  
EBs plated gelatin w/o bFGF 8 days  
Neuron induction w/o growth factors 2 weeks  
Added compound E or compound W 48 h 
Neurons  
βIII-Tubulin+MAP2+ [99] 
Retrovirus  
OCT4, SOX2, KLF4, cMYC  
Human dermal fibroblasts 
Neuronal rosette induction on PA6 stromal cells 11 days  
NPCs isolated by FACS CD184+CD15+CD44−CD271− 
NPC cultured 4 weeks  
Neuron induction-BDNF/GDNF/cAMP 3 weeks  
CD24+CD184−CD44− neurons selected by FACS  
Cultured in BDNF/GDNF/cAMP 5 days 
Neurons  
βIII-Tubulin+MAP2+ >90% 
VGluT1+ 15% GABA+ 8% 
Expressed tetrodotoxin-sensitive  
voltage-activated currents  
GABA+AMPA receptors  
Spontaneous inhibitory/excitatory synaptic 
currents 
[96] 
hESC (I3)  
transduced with lentivirus 
containing mutations in PS1  
iPSC—Retrovirus 
Human dermal fibroblasts (PKa) 
It-NES induction with bFGF+EGF+B27  
Neuron induction—Matrigel w/o factors, 
+N2+B27+cAMP 4 weeks 
Neurons  
βIII-Tubulin+ 80% 
Astrocytes 6% 
[97] 
Trisomy 21  
Retrovirus  
OCT4, SOX2, KLF4, cMYC  
Human dermal fibroblasts 
Matrigel+N2+B27+Noggin+SB431542  
Dissociated and cultured with 3N+bFGF 100 days 
Cortical neurons;  
Early born,  
TBR1+βIII-Tubulin+ 
CTIP2+βIII-Tubulin+ 30% 
Late born,  
BM2+βIII-Tubulin+ 
SATB2+βIII-Tubulin+ 20%–25%  
Functional synapses  
Glutamatergic+ 
PSD95+ 
[100] 
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Table 2. Cont. 
Reprogramming 
Strategy 
Differentiation Protocol Cell Type Formed Reference 
Episomal vectors 
SOX2, KLF4, OCT4, 
L-MYC, LIN28, 
shRNA p53 Human 
dermal fibroblasts 
EB induction DMEM/HamsF12+ 5% KSR+SB431542 8 days  
Neural induction—plated on Matrigel+N2+SB431542 16 days  
Cortical neuron induction—dissociated and cultured in NB 
media+B27+BDNF+GDNF+NT3 48 days  
As above, but on day 58 cortical neuron induction, cells passaged  
Repeated passages on day 96, 126, 156, 176 
Cortical neurons  
SATB2+TBR1+ 
Astrocytes 
[98] 
Retroviral vector 
Klf4, Oct4, Sox2, 
cMyc  
Human fibroblasts 
RA+bFGF 7 days  
Neurosphere formation w/o bFGF 7 days  
Neurospheres cultured with bFGF+EGF 4 days  
Neurospheres cultured with SHH+FGF8 3 days  
Dissociated and transfected with Lhx8/Gbx1-IRES-EGFP 2 days  
Lhx8+/Gbx1+ cells selected by FACS and cultured in NB media+ 
bFGF+NGF 2 weeks (+arabinoside from day 5–10 of NB culture step) 
Basal forebrain cholinergic neurons  
95% MAP2  
66% ChAT  
VaChT+P75R+, NKX2.1+HB9− 
Expessed tetrodotoxin-sensitive voltage-activated 
currents, voltage-gated calcium channels 
[95] 
Lentivirus  
OCT4, SOX2, cMYC, 
KLF4 
Human dermal 
fibroblasts 
Aggregates with iPS cell media 4 days + neural media+N2 2 days  
Aggregates plated on matrigel, Neural media + N2 10 days  
Suspension culture, neural media+B27+N2+cAMP+IGF1 7 days  
Neural rosettes selected manually or Neural Rosette  
selection agent 
Dissociated+plated on Matrigel+NBmedia+N2+B27+ 
cAMP+BDNF+GDNF+IGF1 35 days–76 days 
Neurons  
90% MAP2  
Tau+, βIII-Tubulin+Cux1+Tbr1+PSD95+VGLUT1+ 
Spontaneous activity from microelectrode array 
[103] 
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Table 2. Cont. 
Reprogramming Strategy Differentiation Protocol Cell Type Formed Reference 
MMLV retrovirus  
Oct4, Sox2, Klf4, cMyc  
Human dermal fibroblasts 
Neuronal rosette induction on PA6 stromal cells  
+Noggin and SB431542 6 days  
−Noggin and SB431542 8 days  
CD24+/CD184+/CD271−/CD44− cells selected by FACS  
Cultured in neural media 
(DMEM:F12+N2+B27+BDNF+GDNF+dcAMP) for  
3 weeks w/o bFGF  
CD24+/CD184−/CD44− neurons selected by FACS 
Neurons  
βIII-Tubulin+MAP2+ [101] 
Retrovirus  
OCT4, KLF4, SOX2, cMYC  
Human dermal fibroblasts 
Neuronal progenitor induction using dual-SMAD inhibition 
9 days  
NB media 26 days–46 days 
Neural progenitors  
79% NESTIN+, small pop’n βIII-Tubulin+ 
Neurons 
Active Na+ channels 
K+ channels  
Produce action potentials  
40% neurons Ca2+ spikes 
[102] 
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Electrophysiological recordings also confirmed these cells to express tetrodotoxin sensitive  
voltage-activated currents and have active voltage-gated calcium channels. Together, this gave very 
convincing evidence for functional BFCNs with a relatively high purity. Israel and colleagues also 
performed extensive characterization of their neurons, including electrophysiological recordings. 
However, although 90% of the neurons were βIIITubulin+/MAP2+, the specific types of neurons 
produced remain unclear, with only 15% of neurons expressing VGluT1 and 8% expressing GABA.  
In the case of the cortical neurons generated by Shi and colleagues, these were found to include 
populations of both early and late born cortical neurons. These also formed functional synapses and 
expressed the glutamatergic marker PSD95 [100]. 
7. Modeling Impaired APP Processing from Patient-Specific Induced Pluripotent Stem Cells 
Reveals Considerable Variability 
Varying AD pathologies were analyzed in these articles and all articles had in common an analysis 
of extracellular Aβ. Although some studies were unable to detect Aβ42 (as levels were below the 
detectable limits of the ELISA), it was striking to see how variable levels of Aβ40 were in the patient 
lines in comparison to the control/healthy cells. The familial lines carrying the APP duplication 
(APPDp1/2) had increased Aβ40, although some sporadic lines (sAD1/2) reported no change in Aβ40 
levels [96], and decreased Aβ40 was reported in at least three other familial lines carrying either a 
mutation in APP or PSEN1 [97,98]. Furthermore, increased Aβ42 was only reported in approximately 
one third of the patients [95,98,101,103]. Increased Aβ42:40 was noted in several familial PSEN1 and 
two familial APP(V717I) patient-derived neurons and it was apparent in at least two studies, that this 
elevation was due to increased Aβ42 [101–103]. The variation in observed secreted Aβ products may 
be dependent on the neuronal subtype analyzed, as elevated Aβ42 was observed in three of the five 
patients, where BFCNs were analyzed [95] and in both APP (V717I) patients, where forebrain neurons 
were produced [103]. In addition, increased Aβ42 was also observed in one AD patient, where cortical 
neurons were analyzed [98]. It was only the Down-syndrome-derived cortical neurons that displayed 
both increased secreted Aβ40 and Aβ42 levels [100]. In addition, in the same study, the increased 
Aβ42 was only detectable in neuron cultures that were older than 70 days and in APP (V717I)-derived 
neurons differentiated for 40–50 days, an increase in Aβ42 was also detectable [103]. Interestingly, in 
the case of PSEN1 (E280A) a screening of young pre-symptomatic carriers showed increased levels of 
Aβ42 in both plasma and CSF [105]. These studies therefore report a wide range of results for both 
Aβ40 and Aβ42 and may suggest that it could be necessary to have long-term culture protocols in 
order to see potentially relevant phenotypes. In the case of AD patients, we also know that a variation 
in expression levels of short Aβ peptides exists. For example, Aβ42 levels have been reported to be 
reduced in cerebral spinal fluid of patients compared to controls [106,107], whereas another study 
reported both increased and decreased Aβ42 in AD patients carrying PSEN mutations and decreased 
Aβ40 in the AD patient’s cerebral spinal fluids [108]. It was also interesting to see that the APP 
(V717I) iPS cell-derived neurons had an increase in Aβ38 [103]. Thus, it may be important for future 
studies on AD-derived iPS cells to perform long-term neuronal cultures and compare these directly to 
the Aβ levels in the original patient. 
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The evaluation for the presence of Aβ oligomers has been performed in only one study to date. 
Kondo and colleagues could detect the positive expression of the Aβ oligomer marker, NU1 and 
expression of the low weight oligomer marker, 11A1, in their cortical neurons, specifically localized as 
puncta throughout the neurons from both a familial APP and sporadic AD patient [98]. This was also 
the case for astrocytes generated from the same backgrounds. However, Aβ oligomers were not 
observed in another line, which had increased extracellular Aβ42:Aβ40. Postulation for this difference 
was made by the authors to support a hypothesis that AD may be classified as displaying either an 
extracellular or an intracellular phenotype. 
APP processing was also studied in the AD iPS cell-derived cells by evaluating the effects that  
γ-secretase or β-secretase inhibitors had on the cultured cells. In general, most studies reported a  
decrease of Aβ40 or Aβ42 following treatment of the cells with a γ-secretase or β-secretase  
inhibitor [95–97,99–101]. One study also reported that a γ-secretase inhibitor decreased the production 
of APPsβ [103]. As an exception, two sporadic background iPS cell lines were reported to have 
increased Aβ40 levels following treatment with γ-secretase inhibitors [95]. The authors claimed that 
this may reflect the potential differences in APP processing in early onset disease vs. late onset disease 
as these two lines were derived from patients exhibiting early onset AD, or alternately, it may reflect 
patient-specific differences. 
8. Tau Processing, Cell Death and Oxidative Stress in iPS Cell Lines Modeling AD 
Levels of total and p-tau have been studied in only four of the reports to date. In one study, 
increased p-tau (Thr231) was reported in βIIITubulin+/MAP2+ neurons in two familial AD-iPS carrying 
APP duplications and one sporadic AD-iPS cell line, however, this was not observed in a second 
sporadic AD-iPSC line when compared to control cells [96]. A second study has shown that  
Down-syndrome iPS cell-derived cortical neurons re-localized p-tau (Ser202 and Thr205) to the 
dendrites and cell bodies, which was not observed in the control cortical neurons, where diffuse 
staining was only observed in the axons [100]. Furthermore, this study showed that these neurons also 
secreted higher levels of total tau and p-tau (pSer396 and pThr231) over a 48 h period compared to the 
control neurons. Another study has reported both increased total tau and p-tau (Ser262), however the 
increase in pSer262 was only detectable in iPS cell-derived neurons differentiated for 100 days [103]. 
The final study revealed that no abnormal tau protein accumulation could be detected, or led to the 
production of tangles in two PSEN1-iPS cell neurons [99]. Interestingly, the tau pathology was noted 
in cells obtained from patients carrying mutations in the APP gene and not in the patient cells carrying 
PSEN1 mutations. However, given the limited numbers of studies analyzing p-tau, it may be difficult 
to conclude anything from this outcome. Again, it may be important that longer-term cultured cells are 
studied for such pathology as the latter study of p-tau on PSEN1-iPS was performed on neurons that 
were only 2 weeks old. 
Cell death has only been reported in one study, namely in the Down-syndrome iPS cell-derived 
cortical neurons [100]. Cell death in the neurons was reportedly two-fold higher compared to the 
control neurons and was considered to be due to the secretion of tau into the medium. It was interesting 
to observe that despite some studies reporting increased levels of the toxic Aβ peptide Aβ42, this did 
not lead to increased cell death. In one study, a test on increased susceptibility to cell death by use of 
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glutamate-induced excitation was performed on early sporadic AD iPS cell-derived BFCNs which had 
increased Aβ42 revealing that increased susceptibility could be seen, however this was also observed 
in a late sporadic AD iPS cell line which did not have elevated Aβ42 [95], meaning that the levels of 
increased Aβ42 alone could not be the primary reason for this susceptibility to cell death. 
AD-iPS cell models may also be useful for studying oxidative stress. Whilst reports remain limited 
to date, one report showed that both familial and sporadic AD-iPS lines had increased levels of 
oxidative stress genes [98]. Elevated reactive oxygen species (ROS) was also detected both in the 
analyzed cortical neurons and astrocytes that were generated. Further research is clearly needed to 
further investigate the role of oxidative stress in these cell types compared to other AD in vitro  
cell models. 
9. Hunting for New Genes of Interest in AD 
It is apparent, that with current global gene/protein/lipid expression profiling technologies, human 
cells models of disease could be used to identify potentially new mechanisms. One recent study 
performed gene expression profiling (GEP) on immature neurons carrying PSEN1 FAD mutations and 
discovered several dysregulated genes [102]. Ten upregulated genes and four downregulated genes 
were validated and three upregulated genes, namely NLRP2, ASB9 and NDP were investigated further 
by analyzing publically available GEPs performed on AD hippocampus and cDNA from the temporal 
pole of AD patients. NLRP2, a gene involved in inflammation was actually found to be downregulated 
in human AD temporal pole and no significant difference determined in the AD hippocampus. The 
gene ASB9, an ubiquitin ligase, was found to be upregulated in some AD patient temporal lobes, but 
not in the hippocampi. Finally, NDP, a gene thought to play an important role in CNS development 
was actually found to be significantly decreased in the AD patient hippocampi. Together, this study 
highlights that new genes can be discovered that could be used to pursue new mechanisms related to 
the disease, however, validation in the human brain is still an important and necessary measure to 
confirm the in vitro cell model findings. 
10. Current Use of AD-Modeling Stem Cells for Compound Screening and Drug Testing 
Only a rare cohort of studies has applied the use of stem cells derived from AD models to screen for 
novel compounds of interest or for testing recently identified drugs. These, to date, remain mostly 
restricted to mouse studies and primarily involve ESCs [109] although one study has used a non-AD 
human iPS cell model that is sensitive to Aβ aggregation for such purposes [110]. In one promising 
mouse study, ESCs were differentiated from a mouse model of AD (Tg2576) into an enriched  
population of pyramidal neurons and were subjected to a small molecule library to detect for inhibitors 
of Aβ40 [109]. Four candidate inhibitors were detected to induce over a 40% reduction in Aβ40 levels 
compared to controls, which included amiridine, icariin, phenelzine and progesterone. In the human 
study, healthy iPS cells were differentiated into forebrain neurons and subjected to an Aβ1-42 toxicity 
assay. These cells were then used to screen a GSK proprietary compound library for improvement in 
cell viability, which resulted in 19 hits, including a Cdk2 inhibitor. This field no doubt will grow in the 
coming years and will encompass AD-derived iPS cell lines which will help not only to discover new 
compounds of interest, but could also pave the way for patient-specific therapies. 
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11. Production of AD Isogenic Controls for Potential Gene/Cell Therapy 
With the new revolution in gene editing, research has approached a new frontier for the generation 
of patient-specific cell therapies by correcting the patient’s diseased cells. This of course remains 
relevant for familial cases of AD and cases of known and diagnosed mutations. New techniques in 
genome-editing have been developed, which can be used to repair the particular disease causing 
mutation in a relatively simple manner by using transcription activator-like factor nucleases 
(TALENs), which are artificially produced restriction enzymes that specifically detect and bind to a 
desired nucleotide sequence in the genome and which initiate a double stranded break in the DNA. 
Homologous DNA fragments with the correct sequence need to be provided, so the cells can use these 
as a template to generate the correct sequence and thereby replacing the mutation. This method 
facilitates the generation of isogenic controls and control cell lines, which are absolutely identical to 
the patient iPS cells except for the repaired disease-causing mutation. Another such method is 
facilitated by clustered regularly interspaced short palindromic repeats (CRISPRs). This method is 
potentially faster and easier than the TALEN method. Correction of varying disease-related mutations 
in specific cell types has recently been performed and has even resulted in the correction of the disease 
in new progeny (in mice) when targeted in oocytes [111–117]. Some of these involve correction of 
frame-shifts [116], but it may also be possible to correct for single base pair mutations. One of the 
considered benefits of TALENs and CRISPRs is that there may be no residual ectopic sequences at the 
site of correction, although this depends on the strategy used for selecting for targeted clones, which 
may involve insertion of a selectable cassette. One potential drawback with this strategy is the 
potential to induce off-targeting genetic changes to other genomic sites that have either a similar or the 
same genetic sequence as that of the targeted sequence. The potential of targeting these other sites of 
course may lead to potential alteration in other genes throughout the genome. Such off-targeting has 
been observed in a handful of these studies [112,115,117], and therefore improvements in the design of 
the TALENs and CRISPRs for only the desired recognition target site may be needed before the next 
step to clinical transplantation is taken. To date, there is no literature on successful correction of an AD 
phenotype using either of these technologies; however, this area will no doubt be the focus of the next 
generation of research. Not only will it be important for the generation of healthy patient-specific cells 
that could be potentially transplanted, but corrected cell lines will form the ideal control cells needed 
for a more accurate interpretation of the AD phenotype in the diseased cells, due to the variation 
observed both between patients, but also between healthy age-matched controls. 
12. Current General Limitations of Use of iPS Cells for Disease Modeling 
There are several general limitations regarding the generation of iPS cells and differentiation into 
specific cellular subtypes, which are challenging and not very well understood. General limitations are 
caused by the limited understanding of the nature of iPS cells themselves and by their differentiation 
potential. In particular, the differentiation into a defined neural cell population is currently quite 
challenging. This is mainly because the developmentally relevant proteins and transcription factors, 
which are needed to mimic differentiation into a specific neural cell type, are not yet fully understood. 
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One general problem of using patient-specific iPS cells is the different epigenetic make-up and 
exposure to diverse environmental conditions every individual is facing. These differences have 
implications on comparative studies involving different patient-specific iPS cells, even between 
patients carrying the same pathological mutation. Despite these inter-patient differences, it has also 
been described that the reprogramming event itself can result in significant clone-to-clone variations, 
resulting in non-desired experimental background noise and even generation of non-disease related 
artifacts [118]. Currently, most studies involving the generation of patient-specific iPS cells involve 
the use of age- and gender-matched controls, which results in comparing epigenetically mismatched 
iPS cells. Isogenic controls generated via TALEN or CRISPR gene editing will be much more ideal for 
the study of disease-related cellular phenotypes and for pharmacological screens, which would help 
overcome this limitation. 
Another general challenge is that only some of the aspects of a differentiated, aged cell can be 
restored to the state of pluripotency following reprogramming. Some of these may include an 
elongation of telomeres and restoration of functional mitochondria [119,120]. Other features pertaining 
to the original cell persist following reprogramming, such as acquired mutations, DNA damage, 
epigenetic changes and protein aggregation [121–123]. To date, it is still unclear what effect this has 
on the overall reprogramming efficiency and subsequent differentiation of iPS cells into the desired 
mature cell types. Moreover, iPS cells seem to retain an epigenetic memory, which makes them 
preferentially differentiate into their tissue of origin [124]. 
13. Hurdles Needed to be Overcome in Order to Recapitulate AD Faithfully in a Dish 
One hurdle that needs to be overcome in order to accurately mimic the disease in vitro is the ability 
to produce the most relevant neurons for study. In order to develop in vitro models that can be used to 
screen for novel compounds for possible future treatments, it may be important to focus on areas of the 
brain that are affected earliest, and attempt to model the disease even before the symptoms first arise. 
One hope may be that iPS cells may be able to recapitulate earlier stages of the disease. Since 
Alzheimer’s disease pathology can first be detected in the entorhinal cortex, it might therefore be of 
interest to focus on differentiation of iPS cells into cell types affected in this area of the brain, namely 
pyramidal neurons with glutamate excitation and the varying GABAergic interneurons. It appears that 
it is the long projection neurons that are most vulnerable to developing pathology [18]. Short-axon 
projection cells such as spiny stellate cells apparently resist the pathology [18]. Short-axon local circuit 
cells also avoid pathology with the exception of the axo-axonic cells. It is particularly interesting that 
the vulnerable neurons are either un-myelinated or have only a thin sheath of myelin, as for e.g. 
heavily myelinated Betz cells and Meynert pyramidal cells also resist the pathology [18]. It may even 
be possible in the future to treat pre-symptomatic patients by large-scale screenings of the population. 
This would of course require earlier diagnostic tools for the disease for patients, which are still in 
general lacking, but of which several efforts are being undertaken [125–128]. In the case of the 
hippocampus, it is the CA1 neurons from the temporal medial lobe that are heavily affected by the 
disease, and ideally cross-comparisons with in vitro produced CA3 neurons, which are not affected as 
severely as the CA1 neurons would be ideal, however recapitulating these neurons in vitro is no easy 
task. In the CA1 region, which includes pyramidal neurons of at least three subtypes, there is also the 
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supportive GABAergic interneuron population of which at least 20 different types are known [129]. 
Calretinin positive interneurons and somatostatin/parvalbumin positive interneurons (bistratified 
interneurons) in the CA1 are both affected in earlier stages of the disease [20]. In order to develop such 
protocols, a better understanding of the development of these neurons in vivo is required in order to 
mimic this process ex vivo. In the case of cortical pyramidal neurons, these are produced from 
progenitors located in the neocortical germinal zone in the dorsolateral wall of the telencephalon [130]. 
One recent report has shown the successful generation of cortical pyramidal neurons from both human 
ESC and iPS cells, which could successfully innervate the mouse brain [131], indicating there may be 
a strong future for developing efficient protocols for these cell types. In the case of the interneurons, 
these are generated in the ventral telencephalon and migrate to the neocortex [130]. Furthermore, 
although some markers can be used to distinguish pyramidal neurons from interneurons [129], 
additional markers of these neurons, in particularly, surface-specific markers are needed in order to 
improve selection and purification of these by use of FACS. Even though the brain regions affected by 
AD are composed of several neuronal subtypes as mentioned above, most differentiation protocols 
focus on the derivation of specific neural subtypes, which are mostly affected by the disease. These 
current protocols achieve in some cases good enrichment of a certain neural subpopulation (see Table 2). 
Despite the varying outcomes of different protocols there is also the problem of different results from 
the different iPS cell clones from the same patient cell line. Furthermore, neural differentiation is a 
complex scenario, which is dependent on internal and external morphogenic cues, gene expression and 
transcription factor activity in a spatio-temporal manner [132]. 
Another significant hurdle is overcoming the lack of knowledge of the types of cells that are 
currently being used for analyses. Heterogeneity itself may not be a problem, if we can re-create the 
same heterogeneity observed in the specific regions of the brain affected. However, several different 
approaches and protocols currently exist for differentiation of ESC and iPS cells into cortical  
neurons [100], BFCNs [95], other neurons like dopaminergic neurons mostly affected in Parkinson’s 
disease [133] and astrocytes [134,135]. Some of these differentiation protocols may show variation in 
differentiation efficiency between cell lines, but even from experiment to experiment using the same 
clone but at different time points [136]. 
Many of the differentiation protocols in the AD iPS cell papers to date have produced neurons 
which are βIIITubulin+ and MAP2+ [95–97,99,101] using neuronal induction factors, such as, BDNF, 
GDNF, N2 and B27 (see Table 2). Although it is promising to see phenotypic hallmarks of AD 
recapitulated at a cellular level using these differentiation protocols, there remain variations in the 
phenotypes created. This may be due to the differences in timing of differentiation, some degree of cell 
heterogeneity and the lack of clear understanding of the types of neurons generated. It therefore 
remains difficult to make a direct comparison of the conducted approaches and analyses of AD iPS 
cells. For example, it might well be possible that the observed elevated expression of stress-related 
genes and ROS as well as the formation of Aβ oligomers found in the SATB2+ and TBR1+ neurons is 
only observable in this specific sub-population and not detectable in other βIIITubulin+ and  
MAP2+ neurons. 
In conclusion, there are many differences amongst the final neural cell population generated by the 
differentiation protocols, as well as in the final composition of neural subtypes generated. The 
reproducible detection of an AD related phenotype is very much dependent on the generation of 
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predictable and fully matured brain region-specific neurons. Therefore, it would be relevant to 
combine the phenotypic observations so far gathered and routinely check all AD iPS cell models for 
the presence or absence of all of these disease hallmarks. 
Even though tremendous advances have been made in the generation of AD iPS cells and 
subsequent differentiation into cortical neurons, other neurons and glia, the analysis of the cellular 
disease phenotype is still the most challenging aspect of this cellular model of AD. One of the most 
profound problems is the lack of reliable reproducibility of the differentiation protocols and the clonal 
variation even amongst iPS cell clones from the same patient, which could be responsible for the 
varying outcomes in the results. One explanation could be the incomplete reset of the cellular 
epigenetic landscape to the pluripotent state and current limitations of differentiation protocols, which 
fail to produce functional and specific neuronal subtypes. This could possibly be contributing to the 
observed lack of a disease phenotype and also the diversity in the observed disease phenotypes. One of 
the sporadic AD iPS cell lines showed no phenotype whatsoever, which could mean that there are 
either unknown phenotypic hallmarks related to AD, or simply, in this case, the neurons were not 
matured enough to display a disease phenotype. The lack of mature neuronal differentiation is 
supported by the findings that another APP related mutation (APPV717I) showed a marked increase in 
Aβ42 levels, which increased during the course of the differentiation protocol. A comparative analysis 
of APP and APP cleavage products starting from day 9 until day 100 clearly showed that a significant 
increase of Aβ42 was not detectable before day 40 during the terminal differentiation protocol [103]. 
These two approaches underline the necessity of optimized differentiation protocols in terms of 
duration and timepoint of analyses of the disease phenotype. Another plausible explanation for the 
absence of a cellular SAD phenotype could be due to altered Aβ clearance in the patients. It has been 
shown by several groups that astrocytes may contribute to the Aβ clearance by restricting the 
inflammatory response in the brain [137,138]. Interestingly, APOE4, which is a risk factor for SAD, is 
expressed in astrocytes implying an important functional role of these cells in the neurodegenerative 
progression in the patients [139]. Microglia certainly also play an important role in Aβ clearance [140]. 
These cell types and their impact in AD in vitro systems remain largely unexplored. Nevertheless, it 
was also possible to observe an increase in phosphorylation of tau (Thr231) and an increase in GSK3 
beta activity, in the two APP duplication iPS cell models and in one of the sporadic AD iPS cell 
models [96]. The use of more defined neural subtypes could be more beneficial in dissecting the 
underlying causes of AD progression. These are also encouraging findings for validation in using these 
cellular models to identify cellular changes in AD. Different groups have reported the production of 
AD iPS cells and used different approaches to perform neural differentiation and analyses of these 
cells. This makes it difficult to establish a common cellular phenotype to set as a baseline for AD iPS 
cell models. However, this is very necessary in order to ensure that a lack of phenotype or a novel 
phenotype is not caused by insufficient neural subtype differentiation. 
Overcoming the variation in the AD pathologies of analyzed AD-iPS-derived neural cells is 
important. Whether this variation is reflective of patient variability or cell line variability remains 
unclear. However, one way to overcome this problem would be to make sure at least three clones of 
each patient are produced, and that these produced identical phenotypes. It may also be important to 
have patient medical history that can verify pathology observed when first analyzing results. It is 
evident that not all iPS cell clones recapitulate results, and those that do not should be discarded or 
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eliminated from analyses and interpretation. It is also clear that our lack of understanding of the cell 
types that are being analyzed could impede dramatically on our results and interpretations of them. 
This is a difficult task to overcome, as the complexity of the brain is colossal. It requires significant 
years of basic research into identifying the development cues of the neurons and neural cells of interest 
for the disease. Although, a recent promising study has revealed that 3D brain structures can be 
recreated in vitro from differentiated human embryonic stem cells [141], revealing that it may be 
possible to even recreate specific sub-regions of the brain within a dish in the future. 
14. Future Induction of an AD Phenotype Using Components that Introduce Cellular Stress 
Issues in resetting the biological clock during reprogramming could quite possibly explain the 
difficulties observed in obtaining ideal phenotypes in some AD iPS cell models. This does not come as 
a surprise since AD is a disease in which not only the malfunction of AD related genes, but also the 
aging of cells, as well as the whole organism is involved. This potentially makes the fundamental use 
of in vitro AD iPS cell systems questionable. However, some research groups have started to use 
cellular stresses to provoke accelerated aging in in vitro produced neural cells and have even 
introduced systems, which overexpress genes related to premature aging. This could lead to the 
development of shorter differentiation protocols, which would be of extreme benefit both for 
researchers and for the eventual benefits for patients. 
In one study, it was possible to alleviate Aβ oligomer-induced cellular stress using docosahexaenoic 
acid (DHA) in neurons derived from iPS cells [98]. Since it is known that oxidative stress is a key 
hallmark of Alzheimer’s disease and accelerates the diseases progression [142], ROS could be useful 
in triggering a disease phenotype in SAD iPS cell-derived neurons where no disease phenotype is 
observable or to accelerate the cellular disease and aging process itself. Mitochondria generate energy 
via oxidative phosphorylation and ROS is the byproduct for this energy generation. This observation 
led to the free radical hypothesis of ageing, which makes ROS species responsible for accumulative 
cellular damage over lifetime [143]. Currently, aerobic metabolism and the corresponding generation 
of ROS is still the most widely accepted cause of ageing, but little is known about the intracellular 
targets of ROS and how oxygen manipulation of these influences lifespan [144]. Another widely used 
ROS species is hydrogen peroxide (H2O2), which belongs to the exogenous ROS species, causing 
mostly DNA damage and which induced an apoptotic cellular response at high doses. The usage of this 
kind of stressor has therefore a lasting effect due to the DNA damage; however, it is not clear if these 
mutations directly cause a phenotype. On the other hand, a recent study showed that exposure of rat 
NPCs to H2O2 may actually be beneficial and induce neurogenesis [145], which is in contrast to the 
proposed damaging effect H2O2. This report also showed that low dosages of H2O2 induced 
proliferation of rat NPC cells, and even modified their differentiation potential towards an 
oligodendrocyte fate. This is a particularly interesting aspect since inflammation processes in the brain 
caused by H2O2 have been reported [146]. Unfortunately, the preferred differentiated neural subtype by 
low dosage exposure to H2O2 are oligodendrocytes, which would not be useful in replacing the 
degenerated pyramidal, cortical or cholinergic neurons, which are mostly affected by 
neurodegeneration in AD. Another technique, which is widely used to stress cells, includes serum 
starvation (which in the case of neural cells involves withdrawal of B27). This has been shown to 
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robustly induce autophagy and neural death [147] and therefore a reduction of B27 in the neural media 
could be used to mimic stress and induce autophagy. Currently, none of the AD iPS cell published 
studies have used ROS species or serum starvation to provoke a more profound disease phenotype. 
15. Induction of an AD Phenotype by Manipulating the Gene Expression of Age Inducing genes 
Another possible approach to mimic ageing in a dish could be to activate or repress key regulatory 
genes involved in the ageing process. A recent report revealed that overexpression of progerin (which 
when occurs in humans, causes Hutchinson-Gilford progeria) in an iPS cell model of Parkinson’s 
disease resulted in an accelerated aged phenotype [148]. This cell model revealed pronounced 
dendritic degeneration, progressive loss of tyrosine hydroxylase expression, enlarged mitochondria and 
Lewy-body-precursor inclusions, which are indicative to the fact that the induced ageing was successful. 
Other strategies to induce accelerated aging could involve RNAi-mediated knockdown of relevant 
targets such as sirtuin 1 (SIRT1), repressor element 1-silencing transcription factor (REST) or vacuolar 
protein sorting 41 (VPS41). Further genes of interest have been identified in C. elegans, which are also 
involved in autophagy lysosomal trafficking and shown to convey neuroprotective features. Amongst 
these are autophagy related 7 (ATG7) and PDZ domain containing family, member 1 (GIPC) [149]. 
SIRT1 has been shown to be involved in healthy ageing and longevity [150,151] and appears to be 
neuroprotective in AD [152]. Moreover, REST induces the expression of stress response genes and is 
neuroprotective [153]. VPS41 is involved in lysosomal trafficking and overexpression of this  
protein has been shown to enhance clearance of misfolded alpha synuclein [154]. A knockdown of 
VPS41 appears to hinder the lysosomal complex function and formation and accelerate accumulation 
of toxic misfolded proteins including Aβ. In particular, genes involved in autophagy could be of 
interest since the clearing of misfolded Aβ is believed to occur via autophagy and a downregulation or 
ablation of genes in this pathway could induce ageing as well as enhance the AD phenotype related to 
autophagy. Other studies have implied an important role for Beclin1 in autophagy and even APP 
processing [155], which makes this gene an interesting target as well. Clearly a systematic knockdown 
approach via RNAi targeting components of the autophagy and lysosomal pathways would be an 
amenable approach for identifying suitable targets that could induce ageing and accelerate the cellular 
pathology of AD iPS cell-derived neurons. 
16. Conclusions and Future Perspectives 
There are obviously still some hurdles that need to be overcome before science can faithfully 
recapitulate AD in a dish using iPS cells that might provide benefit to AD patients. It also remains to 
be seen if cell therapy by transplantation of AD-corrected iPS-derived neural cells could be of benefit 
to patients, by assessing integration of grafts into the brain and/or other related effects such as 
inflammation, or if AD-iPS derived disease models could help to deliver new and more advanced 
therapies to the patients. It is clear from the studies performed so far that more research is required. In 
keeping perspective, this research is aimed for the development of new and better medicines that can 
treat the disease long-term, rather than medicines that apply temporary brakes on it, and ultimately we 
are searching for a cure, which may totally alleviate the disease. The benefits to the community both at 
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a societal level, but also at an economical level, are tremendous and would positively benefit millions 
of people around the globe. 
What is evident, however, is that there is a clear step towards translational medicine for pluripotent 
stem cells, and in particular for treatment of disease. This is most striking in the case of other 
neurodegenerative disease such as Parkinson’s disease [156,157]. Ultimately, human iPS cells will 
help to contribute detailed knowledge on AD mechanisms and might even lead to breakthroughs that 
could allow clinicians to develop earlier diagnoses, or be used for patient individualized medication 
and potentially for future cell transplantations. In considering how far we have come with the 
advancement of iPS technologies, and in the few years since the implementation of the technology, it 
is likely that the path ahead will unveil potentially significant advances in the treatment of the disease. 
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